Abstract
Objectives To illustrate the development of the case fatality risk (CFR) for COVID-19 over time using different assumptions for calculating the CFR.
Design Observational study.
Selected European countries, 28 January to October 29 2020.
Participants Laboratory-confirmed COVID-19 cases and deaths due to COVID-19
Main outcome measure case fatality risk (CFR)
Results We show that the CFR has considerably decreased over time. This seems to be driven not only by increased testing but also by a reduced CFR among cases older than 60 years. Our data also confirm a significantly higher fatality risk for men than for women. The decline in the CFR is even more pronounced when only cases and deaths occurring in a specified time window are considered. This alternative estimation method has the advantage that early data where the bias due to the incomplete ascertainment of cases was arguably largest do not affect CFR estimates later on. We find similar results for other European countries.
Conclusion CFR estimates vary considerably depending on the underlying assumptions concerning their calculation. Reliable CFR estimates should not be based on cumulative numbers from the beginning of the pandemic but rather be based on more recent data only.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has not received additional funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used for this study are from open sources and therefore an ethical approval is not required. Data are freely available under https://npgeo-corona-npgeo-de.hub.arcgis.com/datasets/d4580c810204019a7b8eb3e0b329dd6_0/data. and https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-distribution-covid-19-cases-worldwide.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are freely available under https://npgeo-corona-npgeo-de.hub.arcgis.com/datasets/d4580c810204019a7b8eb3e0b329dd6_0/data. and https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-distribution-covid-19-cases-worldwide.
